$10.41-0.22 (-2.07%)
Freenome Inc. (FRNM) is a Medical Specialities company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for FRNM, including 2 SEC filings and 1 earnings update. The most recent was published Nov 12, 2026.
FRNM rankings
Price$10.41-0.22 (-2.07%)
02:30 PM08:45 PM
Financial highlights
Full financials- Net income, TTM
- $109.43M
- Cash
- $180.38M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks3+100%
2026-05-172026-11-08
Mix390d
- SEC Filings2(67%)
- Earnings1(33%)
Activity · 52 weeks32 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
3 items- SECSEC Form 10-Q filed by Freenome Inc.10-Q - Freenome, Inc. (0002017526) (Filer)
- SECFreenome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Freenome, Inc. (0002017526) (Filer)
- PRFreenome Reports Third Quarter 2026 Financial Results– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC – – Entered the public market and raised gross proceeds of $310 million – BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ:FRNM), a personalized cancer detection company using an AI-driven multiomics platform to optimize single- and multi-cancer blood tests, today reported its financial results for the third quarter ended September 30, 2026, and provided guidance for 2026. Third Quarter Financial Highlights Total revenue was $183.5 million for the third quarter of 2026, driven primarily by $180.0 million recognized under our collaboration and license agree
FRNM FAQ
8 questionsWhat does Freenome Inc. do?
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals.What is the latest news on FRNM?
In the last 30 days Quantisnow tracked 3 wire items for FRNM: 2 SEC filings and 1 earnings update. The most recent was published on November 12, 2026.Is FRNM profitable?
Yes. Freenome Inc. earned $109.43M in net income for the twelve months ended Sep 30, 2026.How much cash and debt does FRNM have?
Freenome Inc. reported $180.38M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does FRNM stock trade?
Freenome Inc. (FRNM) is listed on NASDAQ.What sector and industry is FRNM in?
Freenome Inc. operates in the Health Care sector, Medical Specialities industry.What companies are similar to FRNM?
Notable peers in the same industry include GH (Guardant Health Inc.), XGN (Exagen Inc.), NTRA (Natera Inc.), GRAL (GRAIL Inc.). Compare FRNM side-by-side with any of them on Quantisnow.How can I track FRNM on Quantisnow?
Quantisnow aggregates Freenome Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FRNM to receive live email and push alerts on every new disclosure.